With its tumor-restricted activity and far-reaching regulatory roles, DDX5 inhibition offers the prospect of reshaping therapeutic paradigms—not only in pediatric RMS, but across a spectrum of DDX5-dependent malignancies—paving the way for more precise, mechanism-based cancer therapies. The gene discussed is DDX5; the disease is neoplasm.